AU Patent

AU2006270041B2 — Enhanced ocular neuroprotection/neurostimulation

Assigned to Optivue LLP · Expires 2011-08-18 · 15y expired

What this patent protects

An ocular method comprising non-systemic localized ocular administration of a pharmaceutically acceptable formulation and effective concentration of at least one neuro-stimulatory and/or neuro-protective macrolide or other agent for a duration sufficient to enhance viability, con…

USPTO Abstract

An ocular method comprising non-systemic localized ocular administration of a pharmaceutically acceptable formulation and effective concentration of at least one neuro-stimulatory and/or neuro-protective macrolide or other agent for a duration sufficient to enhance viability, confer protection, and/or reduce degeneration of retinal neural cells; enhance corneal sensation and/or ameliorate, and/or prevent ocular scarring. The method is used in a patient having or at risk for developing glaucoma, retinitis pigmentosa, or another ocular neuro-associated disease.

Drugs covered by this patent

Patent Metadata

Patent number
AU2006270041B2
Jurisdiction
AU
Classification
—
Expires
2011-08-18
Drug substance claim
No
Drug product claim
No
Assignee
Optivue LLP
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.